METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Clinical trials for METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Blood test could help doctors switch cancer drugs faster
Disease control Recruiting nowThis phase 2 trial is testing whether a simple blood test that looks for tumor DNA (ctDNA) can help doctors decide when to switch treatments in people with metastatic triple-negative breast cancer. The study compares standard care with a strategy where ctDNA results guide an earl…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Personalized vaccine shows promise in Tough-to-Treat breast cancer trial
Disease control Recruiting nowThis study tests whether adding a personalized vaccine (made from unique tumor proteins) to a combination of chemotherapy and two immunotherapy drugs can better control metastatic triple-negative breast cancer. About 70 participants will be randomly assigned to receive the vaccin…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Experimental drug combo targets Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis early-phase trial tests the safety and best dose of a new drug combination—pidnarulex plus trastuzumab deruxtecan—in people with advanced breast cancer and other solid tumors that have the HER2 protein. The study enrolls 36 adults whose cancer has spread or cannot be surgica…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could a heart drug help immunotherapy fight breast cancer again?
Disease control Recruiting nowThis phase 2 trial tests whether adding the beta-blocker propranolol to the immunotherapy drug pembrolizumab can help shrink tumors in people with metastatic triple-negative breast cancer that has stopped responding to checkpoint inhibitors. About 37 adults with advanced, unresec…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Freezing tumors to supercharge immunotherapy: new hope for aggressive breast cancer?
Disease control Recruiting nowThis early-phase trial tests whether freezing a tumor (cryoablation) can boost the immune response to the drug pembrolizumab in people with metastatic or locally advanced triple negative breast cancer. About 30 participants will be randomly assigned to receive either the combinat…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New Triple-Drug cocktail aims to tackle tough breast cancer
Disease control Recruiting nowThis early-phase trial tests a new drug called ZEN003694 combined with immunotherapy (pembrolizumab) and chemotherapy (nab-paclitaxel) in 57 people with advanced triple-negative breast cancer. The goal is to find a safe dose and see if the combo can shrink tumors or slow the canc…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New Vaccine-Immunotherapy combo targets breast cancer brain metastases
Disease control Recruiting nowThis phase IIa trial tests a combination of a dendritic cell vaccine (targeting HER2/HER3 proteins) and the immunotherapy drug pembrolizumab (Keytruda) in 23 women with breast cancer that has spread to the brain. The vaccine aims to train the immune system to attack cancer cells,…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could a parasite drug boost cancer immunotherapy? new trial investigates
Disease control Recruiting nowThis study tests whether adding ivermectin (a drug used for parasitic infections) to standard immunotherapy drugs (balstilimab or pembrolizumab) can shrink tumors in people with metastatic triple-negative breast cancer. The trial has two phases: first, finding the safest dose of …
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Yuan Yuan • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy offers hope for Hard-to-Treat breast cancer
Disease control Recruiting nowThis study tests whether combining tamoxifen (a hormone blocker) with a targeted form of chemotherapy (liposomal doxorubicin) can shrink tumors in people with advanced triple-negative breast cancer that has spread or cannot be removed by surgery. The trial enrolls 30 adults who h…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to halt spread of aggressive breast cancer
Disease control Recruiting nowThis phase II trial tests whether adding high-dose radiation to standard immunotherapy (pembrolizumab) and chemotherapy can help control metastatic triple-negative breast cancer that is PD-L1 positive. About 29 participants with at least two sites of metastatic disease will recei…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New vaccine trial hopes to train immune system to attack Triple-Negative breast cancer
Disease control Recruiting nowThis study tests a vaccine called STEMVAC, given with chemotherapy, for people with a type of advanced breast cancer (triple-negative) that has spread. The vaccine is designed to teach the body's immune system to find and destroy cancer stem cells. About 20 adults with PD-L1 nega…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Custom-Made vaccine takes on aggressive breast cancer
Disease control Recruiting nowThis early-phase trial is testing a personalized vaccine made from a patient's own tumor, given alone or with immune-boosting drugs (pembrolizumab or ipilimumab), for triple negative breast cancer. The goal is to see if the vaccine is safe and can train the immune system to attac…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
New drug combo aims to fight Hard-to-Treat breast cancer recurrence
Disease control Recruiting nowThis early-phase trial tests whether combining two oral drugs, neratinib and ruxolitinib, is safe and can shrink tumors in people with metastatic triple-negative breast cancer that has come back on the chest wall after chemotherapy. About 20 women will take the drugs daily, and d…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Can an app improve life for metastatic breast cancer patients?
Symptom relief Recruiting nowThis study tests whether a digital platform called Cureety TechCare can improve quality of life and reduce hospitalizations for people with metastatic triple-negative breast cancer starting first-line treatment. Participants will regularly report symptoms through the platform, wh…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: NA • Sponsor: UNICANCER • Aim: Symptom relief
Last updated Jun 26, 2026 12:46 UTC
-
Real-World study tracks ADC effectiveness in advanced breast cancer
Knowledge-focused Recruiting nowThis study follows 100 people with HER2-negative metastatic breast cancer who are receiving antibody-drug conjugates (ADCs) as part of their routine care. Researchers will collect blood samples and medical records to see how long the cancer stays controlled with each ADC treatmen…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC